A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

This first-in-human randomized, double-blind, placebo-controlled, ascending-single and -multiple oral dose study was designed to evaluate the safety, tolerability, and pharmacokinetics in healthy volunteers of KAE609 (cipargamin; formerly NITD609), a spiroindolone now in trials for malaria treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Leong, F. Joel, Li, Ruobing, Jain, Jay Prakash, Lefèvre, Gilbert, Magnusson, Baldur, Diagana, Thierry T., Pertel, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2014
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187895/
https://www.ncbi.nlm.nih.gov/pubmed/25114127
http://dx.doi.org/10.1128/AAC.03393-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187895/
https://www.ncbi.nlm.nih.gov/pubmed/25114127
http://dx.doi.org/10.1128/AAC.03393-14

Ejemplares similares